**Supplemental Table 1. Demographic characteristics and definition of NSAID use in participating studies**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Studies | Country | Male  % | Age, mean | Cases | |  | Controls | | Definition of regular use of NSAIDs |
| **N** | **NSAIDs%** |  | **N** | **NSAIDs%** |
| ARCTIC | Canada | 48.1 | 62.2 | 499 | 18.4 |  | 519 | 30.6 | ≥2 times/week for >1 month 2 years ago |
| ATBC | Finland | 100 | 57.3 | 147 | 23.1 |  | 28 | 28.6 | >1 time/day for ≥1 month |
| CCFR | Canada, Australia,  United States | 48.7 | 55.9 | 2,953 | 21.8 |  | 2,448 | 28.7 | ≥2 times/week for >1 month |
| Colo2&3 | United States | 55.5 | 65.3 | 87 | 25.3 |  | 122 | 46.7 | Currently using |
| CPSII | United States | 51.2 | 68.7 | 537 | 33.7 |  | 526 | 37.6 | ≥15 days/month |
| DACHS | Germany | 60.0 | 68.7 | 2,336 | 23.3 |  | 2,174 | 33.4 | Currently using ≥2 time/week for ≥1 years |
| DALS | United States | 55.1 | 63.9 | 1,103 | 33.4 |  | 1,169 | 42.1 | ≥3 times/week for ≥1 month in 2 years |
| HPFS | United States | 100 | 62.7 | 486 | 45.3 |  | 572 | 50.7 | Currently using ≥2 times/week |
| Kentucky | United States | 48.4 | 62.9 | 937 | 47.7 |  | 1,034 | 53 | ≥1 time/week for ≥1 month |
| MCCS | Australia | 54.0 | 59.8 | 482 | 30.1 |  | 437 | 33.4 | Currently using ≥1 times/week |
| MEC | United States | 53.7 | 63.0 | 323 | 41.8 |  | 341 | 39.6 | ≥2 times/week for ≥1 month |
| MECC | United States | 51.9 | 69.8 | 4,282 | 33.3 |  | 3,395 | 42.8 | ≥1 time/week during the past year |
| NFCCR | Newfoundland | 58.8 | 60.0 | 183 | 30.6 |  | 457 | 38.3 | ≥2 times/week for >1 month |
| NHS | United States | 0 | 58.4 | 811 | 33.8 |  | 1,351 | 40 | Currently using ≥15 days/month |
| PHSa | United States | 100 | 58.9 | 375 | 49.3 |  | 389 | 46.8 | Currently using ≥1 time/week |
| PLCO | United States | 59.3 | 64.2 | 964 | 43.7 |  | 860 | 52.1 | ≥2 times/week in the last 12 months |
| PMH | United States | 0 | 62.7 | 276 | 22.1 |  | 122 | 35.2 | ≥2 times/week for >1 month |
| CRCGEN | Spain | 58.5 | 66.1 | 773 | 22.4 |  | 848 | 32 | Currently using |
| VITAL | United States | 52.8 | 66.4 | 271 | 43.9 |  | 279 | 52.7 | ≥4 days/week for 1 year |
| WHI | United States | 0 | 66.4 | 1,433 | 33.6 |  | 1,526 | 37.4 | ≥1 time/week for at least the last 2 weeks |
| Total |  |  |  | **19,258** | **31.3** |  | **18,597** | **39.2** |  |

ARCTIC (also called OFCCR): Ontario Familial Colorectal Cancer Registry; ATBC: Alpha-Tocopherol, Beta-Carotene Cancer Prevention; CCFR: Colon Cancer Family Registry; Colo 2&3: a case-control study from the University of Hawai’i; CPSII: Cancer Society Cancer Prevention Study II; DACHS: Darmkrebs: Chancen der Verhutüng durch Screening Study; DALS: Diet, Activity and Lifestyle Study; HPFS: Health Professionals Follow-up Study; Kentucky: the Kentucky case-control study; MCCS: Melbourne Case-Control Study (in Melbourne Collaborative Cohort); MEC: Multiethnic Cohort; MECC: Molecular Epidemiology of Colorectal Cancer Study; NFCCR: Newfoundland Case-Control Study; NHS: Nurses’ Health Study; PHS: Physicians’ Health Study; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; PMH: Postmenopausal Hormone Study; CRCGEN: Colorectal Cancer Genetics & Genomics; VITAL: Vitamins and Lifestyle Study; WHI: Women's Health Initiative;

a PHS did not contribute to analysis of regular use of non-aspirin NSAIDs use.